Kymera Therapeutics, Inc. (KYMR) — 10-Q Filings
All 10-Q filings from Kymera Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Kymera's R&D Surge Drives 46% Wider Loss, Cash Reserves Tighten
— Nov 4, 2025 Risk: high
Kymera Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $224.37 million, up from $153.11 mi -
Kymera's Q2 Loss Widens Amid R&D Surge, Collaboration Revenue Dip
— Aug 11, 2025 Risk: high
Kymera Therapeutics, Inc. reported a net loss of $77.8 million for the three months ended June 30, 2025, a significant increase from the $60.2 million net loss -
Kymera Therapeutics Files Q1 2025 10-Q
— May 9, 2025 Risk: medium
Kymera Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including assets like U.S. Treasu -
Kymera Therapeutics Files Q3 2024 10-Q
— Oct 31, 2024 Risk: medium
Kymera Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months en -
Kymera Therapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Kymera Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operat -
Kymera Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 2, 2024 Risk:
Kymera Therapeutics, Inc. (KYMR) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Kymera Therapeutics, Inc. filed a 10-Q report for the period endin
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX